Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Effects of Teverelix DP, a GnRH Antagonist, on Prostate Volume, Urinary Function and Clinical Outcomes in Men Following a First Episode of Acute Urinary Retention (AUR)

NCT07733934 is registered in ClinicalTrials.gov with Antev Ltd. as lead sponsor.

NCT NCT07733934
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07733934 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Effects of Teverelix DP, a GnRH Antagonist, on Prostate Volume, Urinary Function and Clinical Outcomes in Men Following a First Episode of Acute Urinary Retention (AUR)
Lead sponsor
Antev Ltd.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
May 31, 2028
Enrollment
126 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

acute urinary retention, benign prostate hypertrophy(bph)